Sickle Cell Disease Treatment Market - Forecast(2024 - 2030)

Sickle Cell Disease Treatment Market size is estimated to reach $3.8 billion by 2027, growing at a CAGR of 10.6% during the forecast period 2022-2027. Sickle Cell Disease Treatment includes medicines and blood transfusion which target handling the symptoms and averting catastrophes. Sickle cell disease is brought about by a mutation in the haemoglobin-Beta gene found on chromosome 11. The vaso-occlusive crisis, or sickle cell crisis, is a typical painful complexity of sickle cell disease in teenagers and mature grown-ups. Acute episodes of serious pain (crises) are the principal cause that these patients look for medical care in hospital emergency departments. However, usually, the pain is incompletely treated. Acute chest syndrome is one of the most severe issues encountered by people with sickle cell disease (SCD). Haemoglobin A (HbA), also known as adult hemoglobin, hemoglobin A1 or ?2?2, is the most typical human hemoglobin tetramer, responsible for more than 97% of the total red blood cell hemoglobin. The increasing count of patients enduring sickle cell disease which may involve acute chest syndrome is set to drive the Sickle Cell Disease Treatment Market resulting in surging demand for novel medicines that can combat the ailment competently. The proliferating backing of governments to researchers and pharmaceutical firms in their R&D efforts to come up with effective novel treatments is set to propel the growth of the Sickle Cell Disease Treatment Market during the forecast period 2022-2027. This represents the Sickle Cell Disease Treatment Industry Outlook.

Sickle Cell Disease Treatment Market Report Coverage

The report: “Sickle Cell Disease Treatment Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Sickle Cell Disease Treatment Market.

By Disease Type: Sickle Cell Anaemia, Sickle Haemoglobin C Disease, Sickle Beta Thalassemia, Others.
By Treatment Modality: Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant.
By Geography: North America (the U.S, Canada, and Mexico), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), Europe (Germany, France, UK, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), and Rest Of The World (Middle East, Africa).

Key Takeaways

• Geographically, North America Sickle Cell Disease Treatment Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the surging R&D activities involving sickle cell disease and acute chest syndrome, and active healthcare infrastructure in the North American region.
• Sickle Cell Disease Treatment Market growth is being driven by the expanding predominance of sickle cell disease which may involve acute chest syndrome and the associated demand for its suitable treatment. However, the erroneous establishment and application of clinical practice guidelines and lack of a skilled workforce in developing nations are some of the major factors hampering the growth of the Sickle Cell Disease Treatment Market. 
• Sickle Cell Disease Treatment Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Sickle Cell Disease Treatment Market report. 

Sickle Cell Disease Treatment Market: Market Share (%) by Region, 2021

For More Details on This Report - Request for Sample

Sickle Cell Disease Treatment Market Segment Analysis – By Disease Type

The Sickle Cell Disease Treatment Market based on disease type can be further segmented into Sickle Cell Anaemia, Sickle Haemoglobin C Disease, Sickle Beta Thalassemia, and Others. The Sickle Cell Anaemia Segment held the largest market share in 2021. This growth is owing to the increasing cases of sickle cell anemia brought about by a mutation in the gene. Sickle cell disease is brought about by a mutation in the haemoglobin-Beta gene detected on chromosome 11. In sickle cell anemia, the abnormal hemoglobin makes red blood cells to be rigid, sticky, and misshapen. The rising cases of inheritance of sickle cell anemia are further propelling the growth of this segment.

Furthermore, the Sickle Beta Thalassemia segment is estimated to grow with the fastest CAGR of 11.4% during the forecast period 2022-2027 owing to the increasing count of cases of inheritance of a sickle cell allele from one parent and a beta-thalassemia allele from the other with less likelihood of acute chest syndrome.

Sickle Cell Disease Treatment Market Segment Analysis – By Treatment Modality

The Sickle Cell Disease Treatment Market based on treatment modality can be further segmented into Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant. The Blood Transfusion Segment held the largest market share in 2021. This growth is owing to the soaring application of blood transfusion in the treatment of sickle cell disease. Both simple transfusion (ST) of packed red blood cells and automated red cell exchange (RCE) is utilized in the treatment of acute chest syndrome (ACS). The surging application of blood transfusion in the treatment of stroke frequently endured by patients of sickle cell disease is further propelling the growth of this segment.

Furthermore, the Pharmacotherapy segment is estimated to grow with the fastest CAGR of 11.5% during the forecast period 2022-2027 owing to the robust backing of the government for pharmaceutical firms and the increasing application of crizanlizumab to minimize the frequency of vaso-occlusive crisis.

Sickle Cell Disease Treatment Market Segment Analysis – By Geography

The Sickle Cell Disease Treatment Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Sickle Cell Disease Treatment Market) held the largest share with 40% of the overall market in 2021. The growth of this region is owing to the likely introduction of pipeline medications and the increasing adoption of new therapeutics in the region. The presence of a large African-American population in the region affected by sickle cell disease and acute chest syndrome is further propelling the growth of the Sickle Cell Disease Treatment Market in the North American region.

Furthermore, the European region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like large immigration from Western Asia, South Asia, and Africa. The enhanced healthcare services and the neonatal and antenatal screening programs in the diagnosis of sickle cell disease which may involve acute chest syndrome are fuelling the progress of the Sickle Cell Disease Treatment Market in the European region.

Sickle Cell Disease Treatment Market - Drivers

Increasing Predominance Of Sickle Cell Disease In African, Middle-Eastern And South Asian Communities Is Projected To Drive The Growth Of Sickle Cell Disease Treatment Market:

Sickle Cell Disease is brought about by a mutation in the haemoglobin-Beta gene discovered on chromosome 11. Hemoglobin transfers oxygen from the lungs to other parts of the body. Red blood cells with typical hemoglobin (hemoglobin A) are continuous, round and drift by way of blood vessels. As per the World Health Organization – Regional Office For Africa, nearly 5% of the global population carries trait genes for hemoglobin disorders, fundamentally, sickle-cell disease and thalassemia, and more than 300 000 babies with serious hemoglobin ailments are born every year. Sickle cell disease is typical among people of African, Middle Eastern, and South Asian descent. Upsurge in immigration, enhancement in healthcare services, and extensive population of African descent are some of the factors fuelling the growth of the Sickle Cell Disease Treatment Market during the forecast period 2022-2027.

Innovative Novel Medications For Sickle Cell Disease Are Expected To Boost The Demand Of Sickle Cell Disease Treatment:

A novel medication to treat sickle cell disease has been identified in the U.K., the earliest of such medications in 20 years. The medication, crizanlizumab, manufactured by Novartis, has been portrayed as “an innovative treatment” It is introduced into a vein and may be received on its own or alongside standard treatment and regular blood transfusions, as per BBC reports. In a trial, patients receiving the crizanlizumab had a sickle-cell crisis 1.6 times a year on average, in comparison with almost three times a year usually. Crizanlizumab is a medication utilized to minimize the frequency of vaso-occlusive crisis in people aged 16 years and more who have sickle cell anemia. These kinds of ingenious novel medications are driving the growth of the Sickle Cell Disease Treatment Market during the forecast period 2022-2027.

Sickle Cell Disease Treatment Market – Challenges

Exorbitant Cost Of Sickle Cell Treatments And Non-Procurement Of Hydroxyurea Are Challenging The Growth Of The Sickle Cell Disease Treatment Market:

The cost of Sickle Cell Treatments is very high. There are exalted medical costs connected with the disease at about $1 million for patients who attain 45 years, with yearly costs of $10,000 for children and $30,000 for mature grown-ups. These costs may make certain patients discontinue treatment. A large percentage of mature grown-ups with Sickle Cell Disease who endure recurrent pain crises do not procure hydroxyurea, the only Sickle Cell Disease medication endorsed by the U.S. FDA (Food And Drug Administration). When insufficiently treated, Sickle Cell Disease may bring about frequent exhausting pain and raised hazard of stroke, amidst added issues. These issues are hampering the growth of the Sickle Cell Disease Treatment Market.

Sickle Cell Disease Treatment Industry Outlook

Novel product launches, expansions, agreements, joint ventures, partnerships, and acquisitions are key strategies adopted by players in the Sickle Cell Disease Treatment Market. Sickle Cell Disease Treatment top 10 companies include: 

1. Addmedica
2. Emmaus Life Sciences, Inc.
3. Global Blood Therapeutics Inc.
4. bluebird bio, Inc.
5. Pfizer Inc.
6. Novartis
7. Bristol-Myers Squibb Company
8. Teva Pharmaceutical Industries Ltd.
9. CELGENE CORPORATION
10. Ironwood Pharmaceuticals, Inc.

Acquisitions/Product Launches

• In November 2021, Emmaus Life Sciences, Inc. declared that it has entered into an agreement with Asembia to offer extended patient and provider-backed services in order to facilitate access to Endari®, the Company's prescription L-glutamine oral powder for the treatment of sickle cell disease. Particularly, Asembia will offer a single point of contact for benefits examination, financial and co-pay assistance, together with the patient and provider education. Endari® is indicated to minimize the acute complexities of sickle cell disease in mature grown-up and pediatric patients aged five and more.
• In November 2021, Emmaus Life Sciences, Inc. declared a partnership with UpScript IP Holdings, LLC. (UpScript), to provide telehealth solutions to sickle cell disease patients, extending access to Endari®, Emmaus' prescription L-glutamine oral powder for the treatment of sickle cell disease. The telehealth partnership with UpScript will permit patients to connect with a physician without leaving home, thereby removing the hazard of contamination that may happen with hospital visits. Added advantages to patients are inclusive of the capability to acquire same-day physician approval and prescription for Endari and to have the prescription transferred directly to their homes in a matter of few days.
• In December 2020, Emmaus Life Sciences, Inc. declared the introduction of the Endari® Support Program. The Program is targeted to offer patients who are unable to acquire Endari® access to the medicine for nominal or no-cost. Emmaus has partnered with Lash Group’s TheraCom Specialty Pharmacy, a segment of AmerisourceBergen Corporation, to fill prescriptions for Endari® and manage the Program. Endari®, Emmaus’ prescription-grade L-glutamine oral powder, was endorsed by the U.S. Food And Drug Administration (FDA) in July 2017 for treating sickle cell disease in mature grown-up and pediatric patients aged five and more.

Related Reports:

Sickle-cell Anemia Therapeutics Market

Report Code: HCR 84621

Large Cell Lymphoma Market – Forecast (2021 - 2026)

Report Code: HCR 0191

For more Lifesciences and Healthcare Market reports, please click here